Cargando…
Discovery of Icotinib-1,2,3-Triazole Derivatives as IDO1 Inhibitors
Tumor immunotherapy is considered to be a highlight in cancer treatment in recent years. Indoleamine 2,3-dioxygenase 1 (IDO1) is closely related to the over expression of many cancers, and is therefore a promising target for tumor immunotherapy. To search for novel IDO1-targeting therapeutic agents,...
Autores principales: | Mao, Long-fei, Wang, Yu-wei, Zhao, Jie, Xu, Gui-qing, Yao, Xiao-jun, Li, Yue-Ming |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7555427/ https://www.ncbi.nlm.nih.gov/pubmed/33101032 http://dx.doi.org/10.3389/fphar.2020.579024 |
Ejemplares similares
-
Discovery of Novel 1,2,3-triazole Derivatives as IDO1 Inhibitors
por: Hou, Xixi, et al.
Publicado: (2022) -
Novel 1,2,3-Triazole Erlotinib Derivatives as Potent IDO1 Inhibitors: Design, Drug-Target Interactions Prediction, Synthesis, Biological Evaluation, Molecular Docking and ADME Properties Studies
por: Xu, Gui-Qing, et al.
Publicado: (2022) -
Synthesis and Antitumor Activity of Erlotinib Derivatives Linked With 1,2,3-Triazole
por: Deng, Peng, et al.
Publicado: (2022) -
Icotinib derivatives as tyrosine kinase inhibitors with anti-esophageal squamous carcinoma activity
por: Chen, Xiaojie, et al.
Publicado: (2022) -
Design, synthesis and biological evaluation of erlotinib-based IDO1 inhibitors
por: Hou, Xi-xi, et al.
Publicado: (2022)